CymaBay Therapeutics

We are a global clinical-stage biopharma company
developing solutions for patients with liver diseases.

[CymaBay Therapeutics @CymaBay]

As CymaBay is now part of @GileadSciences, this account is no longer active. We look forward to advancing our shared mission. Thank you for your support.

[CymaBay Therapeutics @CymaBay]

Primary biliary cholangitis (PBC) is a rare, chronic, autoimmune liver disease that progressively destroys the liver’s bile ducts. Learn more about PBC here: https://t.co/DS54mz7U40

[CymaBay Therapeutics @CymaBay]

Learn more about the unmet needs in #PrimaryBiliaryCholangitis today and how @GileadSciences is working to create a healthier future for people living with #PBC and #LiverDisease.

[Gilead Sciences @GileadSciences]

Learn about the unmet needs of people living with #PrimaryBiliaryCholangitis (PBC) and the advances in research that aim to improve liver health and quality of life.

[CymaBay Therapeutics @CymaBay]

As #EASLCongress closes, we are grateful to have shared our latest findings and connected with stakeholders from across #PrimaryBiliaryCholangitis and #hepatology as we continue working to improve PBC care. Thanks, @EASLnews, for bringing this incredible community together!

[CymaBay Therapeutics @CymaBay]

At @EASLnews #EASLCongress, we will share interim long-term data from our ASSURE study of our investigational therapy in people living with #PrimaryBiliaryCholangitis. Learn more: https://t.co/AFdlCCEoh7

[CymaBay Therapeutics @CymaBay]

The myth that #PrimaryBiliaryCholangitis doesn’t impact men can delay diagnosis. This #MensHealthMonth, we encourage men to prioritize their #LiverHealth by talking to a doctor if experiencing common PBC symptoms like intense itch or fatigue. Learn more: https://t.co/YiydRP4sIZ

[CymaBay Therapeutics @CymaBay]

We are looking forward to #EASLCongress 2024 next week and meeting with hepatology experts from around the world as we work to advance care for people living with #PrimaryBiliaryCholangitis. Please visit: https://t.co/VH1Sm73uPt

[CymaBay Therapeutics @CymaBay]

Thank you @DDWMeeting for another impactful meeting. It was great to connect with experts from across the U.S. passionate about advancing care for people living with #LiverDiseases and #PrimaryBiliaryCholangitis. #DDW2024

[CymaBay Therapeutics @CymaBay]

We are proud to present our latest research in primary biliary cholangitis at #EASLCongress 2024 as part of Gilead’s research across liver diseases.

Learn more at: https://t.co/vGxqB2vXQg

[Gilead Sciences @GileadSciences]

#GileadNews: We’ll share the latest data from our liver disease franchise at #EASLCongress, underlining our drive for life-changing science to create healthier futures for people living with liver disease. Read more: https://t.co/24GiJb2VmD

[CymaBay Therapeutics @CymaBay]

On #ClinicalTrialsDay we join @ACRPDC to recognize the critical progress made by clinical research and thank every participant that has taken part in a clinical study to help advance care in #PrimaryBiliaryCholangitis. Learn about our ongoing studies: https://t.co/kmRa9yUS6Q

[CymaBay Therapeutics @CymaBay]

At @DDWMeeting #DDW2024, we will share results from our ongoing ASSURE study demonstrating further evidence of the efficacy and safety profile of our investigational therapy for #PrimaryBiliaryCholangitis. Learn more: https://t.co/krT86xf3zB

[CymaBay Therapeutics @CymaBay]

This #WomensHealthMonth, we encourage women to prioritize their #LiverHealth and speak up if experiencing itch or fatigue, symptoms of #PrimaryBiliaryCholangitis, a chronic, autoimmune liver disease. Learn more here: https://t.co/OH4E1yny1Q

[CymaBay Therapeutics @CymaBay]

Last week, we welcomed some new recruits to our team on #BringYourChildToWorkDay. It was a day full of fun activities and #STEM experiments to inspire us all. They did a great job in their final presentation!

[CymaBay Therapeutics @CymaBay]

On #WorldLiverDay, we recognize the liver's central role in a myriad of vital functions in the body. With chronic liver disease on the rise, education surrounding #LiverHealth is so important. Watch to learn more about #PrimaryBiliaryCholangitis, a rare liver disease.

[CymaBay Therapeutics @CymaBay]

“Empowering Connections in PBC” was the theme at this year's @PBCers conference. Onsite we learned from people living with #PrimaryBiliaryCholangitis and their families and were so inspired by their stories. For resources on getting support, please visit: https://t.co/URQHos45qq

[CymaBay Therapeutics @CymaBay]

At the #pbcSummit we joined advocates from around the world working to improve the lives of people with #PrimaryBiliaryCholangitis. Their passion and ideas inspired us and we left with lots to consider for our work ahead. Thank you @PBCFoundation for leading this impactful event!

[CymaBay Therapeutics @CymaBay]

#DYK that more than 50% of people with autoimmune diseases, like #PrimaryBiliaryCholangitis (PBC), can experience depression and anxiety? Learn more about the importance of holistic health approaches for people with PBC: https://t.co/0EZt0yNAM6

[CymaBay Therapeutics @CymaBay]

We are pleased to be onsite at the @CLDFoundation #LiverConnect Conference to discuss the latest research in #PrimaryBiliaryCholangitis. Check out the program: https://t.co/iRnWLP8Ke9

[CymaBay Therapeutics @CymaBay]

Today we become a wholly owned subsidiary of @GileadSciences. We’ve always been dedicated to advancing life-changing treatments, and together we’ll be able to further our commitment to improve the lives of people with liver disease. https://t.co/xF3qJ26tgU

[CymaBay Therapeutics @CymaBay]

We are pleased to be onsite with the European liver community at the Paris Hepatology Conference discussing the impact of Primary Biliary Cholangitis (PBC). For more information, visit: https://t.co/C81SP5dsVA

#HybridPHC2024